News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Readies $13.5 Billion Bid for BioMarin Pharmaceutical Inc. (BMRN), Not Alexion Pharmaceuticals Inc. (ALXN)


9/19/2013 7:23:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Shares of BioMarin Pharmaceutical Inc. surged prior to the market's opening Thursday after a report that Genentech Inc. parent Roche Holding AG is assembling $15 billion in debt financing to buy the rare-drug developer. But Roche quickly shot down the rumor.

DealReporter said Roche may pay $95 to $105 per share for San Rafael-based BioMarin (NASDAQ: BMRN), according to Bloomberg, which would value the company at roughly $13.5 billion. DealReporter said UBS AG would lead the financing with $5 billion.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES